Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study.
CIDP
Deltaproteobacteria
Faecalibacterium
MG
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
01
2021
accepted:
08
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with gut microbiota considered to be a pathogenetic factor. Previous pilot studies have found differences in the gut microbiota of patients with MG and healthy individuals. To determine whether gut microbiota has a pathogenetic role in MG, we compared the gut microbiota of patients with MG with that of patients with non-inflammatory and inflammatory neurological disorders of the peripheral nervous system (primary endpoint) and healthy volunteers (secondary endpoint). Faecal samples were collected from patients with MG ( No differences were found in alpha- and beta-diversity indices computed between the MG, NIND and CIDP groups, indicating an unaltered bacterial diversity and structure of the microbial community. However, the alpha-diversity indices, namely Shannon, Chao 1 and abundance-based coverage estimators, were significantly reduced between the MG group and healthy volunteers. Deltaproteobacteria and Although the overall diversity and structure of the gut microbiota did not differ between the MG, NIND and CIDP groups, the significant difference in the abundance of Deltaproteobacteria and
Sections du résumé
BACKGROUND
BACKGROUND
Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with gut microbiota considered to be a pathogenetic factor. Previous pilot studies have found differences in the gut microbiota of patients with MG and healthy individuals. To determine whether gut microbiota has a pathogenetic role in MG, we compared the gut microbiota of patients with MG with that of patients with non-inflammatory and inflammatory neurological disorders of the peripheral nervous system (primary endpoint) and healthy volunteers (secondary endpoint).
METHODS
METHODS
Faecal samples were collected from patients with MG (
RESULTS
RESULTS
No differences were found in alpha- and beta-diversity indices computed between the MG, NIND and CIDP groups, indicating an unaltered bacterial diversity and structure of the microbial community. However, the alpha-diversity indices, namely Shannon, Chao 1 and abundance-based coverage estimators, were significantly reduced between the MG group and healthy volunteers. Deltaproteobacteria and
CONCLUSION
CONCLUSIONS
Although the overall diversity and structure of the gut microbiota did not differ between the MG, NIND and CIDP groups, the significant difference in the abundance of Deltaproteobacteria and
Identifiants
pubmed: 34394728
doi: 10.1177/17562864211035657
pii: 10.1177_17562864211035657
pmc: PMC8361534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562864211035657Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: AT and TH are members of the medical advisory board of the German Myasthenia Society.
Références
PLoS One. 2014 Sep 17;9(9):e107909
pubmed: 25229475
EMBO Rep. 2014 Sep;15(9):991-9
pubmed: 25074018
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
J Neuroimmunol. 2008 Sep 15;201-202:33-40
pubmed: 18675462
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22402-22412
pubmed: 32839304
JAMA Neurol. 2021 Apr 1;78(4):426-433
pubmed: 33555314
J Neuroophthalmol. 2016 Mar;36(1):29-32
pubmed: 26035808
Mol Biol Cell. 2006 Feb;17(2):623-33
pubmed: 16280358
J Neuroimmunol. 2010 Aug 25;225(1-2):123-31
pubmed: 20472307
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718
pubmed: 28893978
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Nucleic Acids Res. 2009 Jan;37(Database issue):D141-5
pubmed: 19004872
Handb Clin Neurol. 2008;91:253-72
pubmed: 18631846
Nat Commun. 2017 Dec 5;8(1):1784
pubmed: 29209090
J Peripher Nerv Syst. 2014 Mar;19(1):2-13
pubmed: 24612201
Front Microbiol. 2018 Nov 09;9:2627
pubmed: 30483222
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Immunology. 2005 Sep;116(1):134-41
pubmed: 16108825
J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):981-987
pubmed: 30992333
Curr Opin Immunol. 2012 Aug;24(4):392-7
pubmed: 22673877
Clin Immunol. 2008 Feb;126(2):180-8
pubmed: 18054287
Nat Commun. 2020 Jan 17;11(1):362
pubmed: 31953381
Gut Microbes. 2020 Nov 9;12(1):1667723
pubmed: 31583949
J Peripher Nerv Syst. 2008 Mar;13(1):54-63
pubmed: 18346231
BMC Neurol. 2010 Jun 18;10:46
pubmed: 20565885
Immunol Lett. 2009 Jan 29;122(1):52-7
pubmed: 19111574
Bioinformatics. 2014 Nov 1;30(21):3123-4
pubmed: 25061070
Front Endocrinol (Lausanne). 2020 Dec 04;11:586529
pubmed: 33343507
Int Immunopharmacol. 2020 Nov;88:107024
pubmed: 33182024
J Crohns Colitis. 2013 Dec;7(11):e558-68
pubmed: 23643066
J Neurol. 2016 Aug;263(8):1473-94
pubmed: 26886206
Nature. 2013 Aug 8;500(7461):232-6
pubmed: 23842501
Autoimmunity. 2004 Jun;37(4):317-9
pubmed: 15518050
Adv Sci (Weinh). 2019 Jul 31;6(18):1901441
pubmed: 31559142
Ther Adv Neurol Disord. 2015 Nov;8(6):316-27
pubmed: 26600875
Science. 2011 Jan 21;331(6015):337-41
pubmed: 21205640
Int J Syst Evol Microbiol. 2002 Nov;52(Pt 6):2141-2146
pubmed: 12508881
Lab Invest. 2009 Nov;89(11):1195-220
pubmed: 19770840
Transpl Infect Dis. 2021 Feb;23(1):e13397
pubmed: 32609940
J Microbiol Methods. 2010 Feb;80(2):209-11
pubmed: 19995580
Sci Rep. 2019 Nov 8;9(1):16396
pubmed: 31705027
Eur J Neurol. 2010 Mar;17(3):356-63
pubmed: 20456730
Sci Rep. 2018 Sep 26;8(1):14384
pubmed: 30258104
Bioinformatics. 2011 Aug 15;27(16):2194-200
pubmed: 21700674
Cells. 2019 Jul 02;8(7):
pubmed: 31269763